SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Principal Investigator
Jason Efstathiou, MD, Dphil,
Status
Closed to Accrual
Date Opened To Accrual
April 19 2019
Date Closed to Accrual
April 01 2024
Disease Site
Genitourinary [GU]
Bladder
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).
NOTE:
This is a Joint SWOG & NRG Oncology FDA registration-intent trial. NRG Oncology institutions can credit NRG for their case accrual. NRG Canadian member sites must credit the Canadian Clinical Trials Group (CCTG).
SWOG Study Chair: Parminder Singh, M.D.
Patient Population
Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0).
Target Accrual
475
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.